News

Afinitor (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease. Based on results from this study and other early-stage research,

Alnylam and Cubist have reported preliminary data from their Phase II study of Aln-Rsv01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection.

Rx for Africa has announced the signing of letter of intent for a strategic alliance with Rusan Pharma of Mumbai, India. The alliance commences immediately, with Rusan providing

Sangamo has announced positive Phase-II clinical data from its ZFP Therapeutic program, to develop SB-509 as a treatment for diabetic neuropathy (DN). Data from SB-509-601 and SB-509-701A Phase

Micromet has announced that the German Multicenter ALL Study Group (GMALL) presented phase-II clinical data of the BiTE antibody blinatumomab (MT103) at the 14th Congress of the European

Lundbeck and Takeda jointly announced headline results from the first three clinical trials in the phase III development program with Lu AA21004, in major depressive disorder (MDD). Previously

AEterna Zentaris, after regaining from Ardana the worldwide rights to the growth hormone secretagogue (GHS)/ghrelin agonist, AEZS-130, has signed an agreement with Ardana to acquire all its assets

Rexahn has announced that it has completed its registered direct offering of common stock and warrants. Rodman & Renshaw acted as the exclusive placement agent for this transaction.

China Biologic Products has entered into a securities purchase agreement with certain accredited investors led by Essence International Investment. As per the deal, the company will issue 3.8%